Amgen Inc.

BUL:AM1 Stock Report

Market Cap: €153.7b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Amgen Valuation

Is AM1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AM1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AM1 (€288.03) is trading below our estimate of fair value (€552.88)

Significantly Below Fair Value: AM1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AM1?

Key metric: As AM1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AM1. This is calculated by dividing AM1's market cap by their current earnings.
What is AM1's PE Ratio?
PE Ratio53.6x
EarningsUS$3.13b
Market CapUS$167.92b

Price to Earnings Ratio vs Peers

How does AM1's PE Ratio compare to its peers?

The above table shows the PE ratio for AM1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average249.4x
REGN Regeneron Pharmaceuticals
17.2x7.6%US$80.0b
GILD Gilead Sciences
887.8x40.9%US$110.5b
CSL CSL
32.9x13.0%AU$133.9b
ABBV AbbVie
59.7x28.1%US$296.5b
AM1 Amgen
53.6x23.6%€167.9b

Price-To-Earnings vs Peers: AM1 is good value based on its Price-To-Earnings Ratio (53.6x) compared to the peer average (79.6x).

Price to Earnings Ratio vs Industry

How does AM1's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AM1 53.6xIndustry Avg. 26.9xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AM1 is expensive based on its Price-To-Earnings Ratio (53.6x) compared to the European Biotechs industry average (31.2x).

Price to Earnings Ratio vs Fair Ratio

What is AM1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AM1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio53.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AM1's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AM1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€294.25
0%
16.5%€348.65€155.57n/a23
Nov ’25n/a
€294.25
0%
16.5%€348.65€155.57n/a23
Oct ’25n/a
€294.25
0%
16.5%€348.65€155.57n/a23
Sep ’25n/a
€294.25
0%
16.5%€348.65€155.57n/a23
Aug ’25€313.30
€292.24
-6.7%
15.5%€349.33€156.28n/a24
Jul ’25€295.13
€295.65
+0.2%
15.4%€355.03€158.83n/a24
Jun ’25€276.88
€291.51
+5.3%
15.4%€350.25€156.69n/a24
May ’25€255.38
€284.21
+11.3%
16.7%€356.14€159.32n/a25
Apr ’25€264.70
€281.95
+6.5%
16.7%€350.85€156.96n/a25
Mar ’25€256.40
€282.57
+10.2%
16.9%€352.83€157.85n/a24
Feb ’25€292.40
€268.89
-8.0%
16.1%€323.16€170.81n/a24
Jan ’25€260.30
€255.79
-1.7%
14.8%€305.39€168.15n/a24
Dec ’24€248.40
€253.09
+1.9%
14.5%€308.04€169.61n/a24
Nov ’24€243.40
€259.94
+6.8%
14.4%€317.96€175.07n/a23
Oct ’24€254.90
€245.58
-3.7%
14.1%€299.49€173.14n/a20
Sep ’24€238.70
€233.32
-2.3%
14.5%€284.15€160.41n/a20
Aug ’24€212.60
€225.30
+6.0%
13.7%€266.01€158.34€313.3020
Jul ’24€203.30
€235.80
+16.0%
14.2%€302.25€162.75€295.1320
Jun ’24€197.85
€235.80
+19.2%
14.2%€302.25€162.75€276.8820
May ’24€213.80
€231.25
+8.2%
14.3%€296.24€159.51€255.3820
Apr ’24€221.45
€236.88
+7.0%
14.7%€302.90€163.10€264.7019
Mar ’24€216.88
€237.54
+9.5%
14.8%€303.13€163.22€256.4019
Feb ’24€224.40
€237.40
+5.8%
14.8%€295.85€163.85€292.4019
Jan ’24€245.25
€249.41
+1.7%
15.2%€306.18€169.58€260.3019
Dec ’23€269.85
€247.26
-8.4%
15.0%€311.94€172.76€248.4018
Nov ’23n/a
€256.47
0%
12.0%€299.10€184.53€243.4021

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Evotec

€1.8b

Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.

EVT

€8.82

7D

0%

1Y

n/a

Valneva

€331.2m

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

AYJ

€2.08

7D

-9.8%

1Y

-61.5%

Merck KGaA

€60.1b

Operates as a science and technology company in Germany.

MRK

€138.25

7D

-4.2%

1Y

n/a